Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ex Vivo Immunity to S. aureus Vaccine Antigens in Hemodialysis Patients
NCT03643328Completed
- Sponsor
- CHU Saint-Etienne
- Start
- Dec 2017
- Primary completion
- Dec 2020
- Countries
- 1
01
Overview
Single-arm trial, sponsored by CHU Saint-Etienne. Primary endpoints: Functional capacity of neutrophils to S. aureus vaccine antigens up to 12 months, Induction of oxidative burst to S. aureus vaccine antigens up to 12 months and 3 more. Started Dec 2017; status: completed.
Beyond the preview
Go deeper on NCT03643328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03643328.